ACOG - הכנסה לפני ניכוי ריבית, מסים ופחת Alpha Cognition

Alpha Cognition relies on a North American base for the development of Alzheimer's therapies. A strategic alliance with dementia centers is accelerating the market launch of Zunveyl, while preparations for the commercial release are expanding neurological research. The underlying EBITDA confirms the issuer's financial stability, with the current parameter equal to 0.00.

Alpha Cognition expenditures on promoting its Alzheimer's drug are creating a temporary liquidity deficit, making the monitoring of net cash receipts from sales before interest and taxes critical. The current value of 0.00 allows for a real-time assessment of operational efficiency, while sharp spikes in operating cash flow before interest and taxes may signal an asset overvaluation.